Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 10226 - 10250 of 12439 in total
PN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis. It is being developed by Peptech.
Investigational
Fibrinolysin consists of two polypeptide chains, one light and one heavy, linked by a disulfide bond. The light chain has a molecular weight of approximately 27,000 Da and contains the active center of Fibrinolysin; the heavy chain has a molecular weight of approximately 57,000 Da. Fibrinolysin is used as a...
Investigational
Matched Description: … The light chain has a molecular weight of approximately 27,000 Da and contains the active center of Fibrinolysin ... ; the heavy chain has a molecular weight of approximately 57,000 Da. ... Fibrinolysin consists of two polypeptide chains, one light and one heavy, linked by a disulfide bond. …
Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions. While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are ongoing or completed evaluating its use in atopic dermatitis,[L40604,L40619,L40629] ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis,...
Experimental
Investigational
Matched Description: … treatment of various immuno-inflammatory conditions. ... Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the ... While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are …
XL281 is a novel anticancer compound designed to potently inhibit the RAS/RAF/MEK/ERK signaling pathway. Mutational activation of RAS occurs in about 30 percent of all human tumors, including non-small cell lung, pancreatic, and colon cancer. XL281 is a specific inhibitor of RAF kinases, including the mutant form of B-RAF, which...
Investigational
Matched Description: … in 60 percent of melanomas, 24-44 percent of thyroid cancers, and 9 percent of colon cancers. ... Mutational activation of RAS occurs in about 30 percent of all human tumors, including non-small cell ... XL281 is a specific inhibitor of RAF kinases, including the mutant form of B-RAF, which is activated …
First described in the literature in 2004, N-(2-Aminoethyl)-1-aziridineethanamine is an experimental angiotensin converting enzyme 2 inhibitor investigated for its use in treating cardiovascular disease and its activity against Severe Acute Respiratory Syndrome (SARS).
Experimental
RDEA806 is a new HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to resistance and a broad spectrum of activity.
Investigational
Matched Description: … reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to resistance and a broad spectrum of
Biropepimut-S is under investigation in clinical trial NCT02873819 (Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity).
Investigational
Matched Description: … (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity ... Biropepimut-S is under investigation in clinical trial NCT02873819 (Safety and Efficacy Study of GL-0817 …
AZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19. It was developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 - a significantly longer window of efficacy than that...
Investigational
Matched Description: … against COVID-19 - a significantly longer window of efficacy than that of other vaccines. ... [L15596] It was developed by AstraZeneca with the goal of conferring at least 6 months of protection ... trials for the prevention and treatment of COVID-19. …
Etesevimab (LY-CoV016, also known as JS016) is a fully human and recombinant monoclonal antibody that targets the SARS-CoV-2 surface spike protein receptor binding domain.[L16651,L16661] Under the EUA granted in February 2021, etesevimab is used in combination with bamlanivimab to treat mild to moderate COVID-19 in adults and pediatric patients who...
Investigational
Matched Description: … [L40174] The EUA currently allows bamlanivimab and etesevimab for post-exposure prophylaxis of COVID- …
Didesmethylrocaglamide is a naturally-occurring derivative of rocaglamide and belongs to a class of anti-cancer phytochemicals referred to as "rocaglamides" derived from plants of the genus Aglaia. While traditionally used for their insecticidal benefits, this class of compounds is now being studied for use as chemotherapeutic agents in the treatment of...
Experimental
Matched Description: … Didesmethylrocaglamide is a naturally-occurring derivative of [rocaglamide] and belongs to a class of ... [A186802,A186763,A186781,A186784] Of the known derivatives of rocaglamide, didesmethylrocaglamide appears ... anti-cancer phytochemicals referred to as "rocaglamides" derived from plants of the genus _Aglaia_. …
TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders. TTP889 is the only known selective small molecule inhibitor of Factor IX, a key enzyme of the intrinsic pathway of the blood coagulation system. TTP889 has proven...
Investigational
Matched Description: … TTP889 is the only known selective small molecule inhibitor of Factor IX, a key enzyme of the intrinsic ... pathway of the blood coagulation system. ... as an anticoagulant for the treatment of thromboembolic disorders. …
Dectrekumab is under investigation in clinical trial NCT00987545 (Efficacy 2 Part Study of Identification of Keloid Biomarkers and Effect of QAX576 on Keloid Recurrence).
Investigational
Matched Description: … of Keloid Biomarkers and Effect of QAX576 on Keloid Recurrence). ... Dectrekumab is under investigation in clinical trial NCT00987545 (Efficacy 2 Part Study of Identification …
The novel indole-ether quinazoline Cediranib is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily oral therapy for the treatment of cancer.
Investigational
Matched Description: … It is being developed clinically as a once-daily oral therapy for the treatment of cancer. ... quinazoline Cediranib is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of
ND7001, a selective PDE2 inhibitor is in clinical trials for the treatment of depression. ND7001 is a solid. Known drug targets of ND7001 including phosphodiesterase 2A, cGMP-stimulated and cGMP-dependent 3',5'-cyclic phosphodiesterase. It is a new type of antidepressant drug with anxiolytic activity. It is the first representative of a new...
Investigational
Matched Description: … It is the first representative of a new generation of psycho-active compounds potentially devoid of several ... It is a new type of antidepressant drug with anxiolytic activity. ... ND7001, a selective PDE2 inhibitor is in clinical trials for the treatment of depression. …
Rozrolimupab is a recombinant polyclonal antibody consisting of 25 different anti-Rhesus D (RhD) antibodies to replace existing anti-RhD hyperimmune immunoglobulins for the treatment of Idiopathic Thrombocytopenic Purpura (ITP) and the prevention of Hemolytic Disease of Newborns (HDN).
Investigational
Matched Description: … Purpura (ITP) and the prevention of Hemolytic Disease of Newborns (HDN). ... Rozrolimupab is a recombinant polyclonal antibody consisting of 25 different anti-Rhesus D (RhD) antibodies ... to replace existing anti-RhD hyperimmune immunoglobulins for the treatment of Idiopathic Thrombocytopenic …
CS-917 is a novel inhibitor of fructose 1,6-bisphphosphatase (FBPase) which is one of the rate-limiting enzymes of gluconeogenesis.
Investigational
Matched Description: … enzymes of gluconeogenesis. ... CS-917 is a novel inhibitor of fructose 1,6-bisphphosphatase (FBPase) which is one of the rate-limiting …
Cx501 is used to treat epidermolysis bullosa (EB), a rare genetic condition which can lead to contraction of the joints, fusion of fingers and toes, contraction of the mouth membranes and narrowing of the oesophagus. It is developed by Cellerix and is in phase I of clinical trials.
Investigational
Matched Description: … the joints, fusion of fingers and toes, contraction of the mouth membranes and narrowing of the oesophagus ... It is developed by Cellerix and is in phase I of clinical trials. ... is used to treat epidermolysis bullosa (EB), a rare genetic condition which can lead to contraction of
AX200, which has been developed for the treatment of stroke, is the most advanced drug candidate and is halfway through the process of gaining clinical approval. The expression of the endogenous AX200 protein in the brain is increased after brain damage. Thus, if this drug administered in the acute phase...
Investigational
Matched Description: … stroke, while stimulating simultaneously the regeneration of nervous tissue through the induction of ... is halfway through the process of gaining clinical approval. ... neuro- and arteriogenesis and supporting the reorganisation of the nervous system. …
Alzheimer's disease (AD) is the most common cause of dementia in elderly patients, with classical histopathological hallmarks including extracellular amyloid-beta (Aβ) plaques and intraneuronal neurofibrillary tangles (NFTs). As the classical view of AD pathology posits that Aβ accumulation triggers tau hyperphosphorylation and aggregation to form NFTs and cause neurodegeneration, large...
Investigational
Matched Description: … As the classical view of AD pathology posits that Aβ accumulation triggers tau hyperphosphorylation and ... Alzheimer's disease (AD) is the most common cause of dementia in elderly patients, with classical histopathological ... Despite the clear association of Aβ aggregation with AD, treatments aimed at preventing Aβ aggregation …
TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical development. mTOR inhibitors are currently used in the prevention of organ rejection in transplantation, the treatment of autoimmune and oncological diseases, and as a component of coated stents for the treatment of coronary...
Investigational
Matched Description: … of coronary artery disease. ... , the treatment of autoimmune and oncological diseases, and as a component of coated stents for the treatment ... TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical …
ICA-105665 is a novel small molecule compound for the treatment of epilepsy. It is a novel opener of the KCNQ ion channel which in preclinical studies has demonstrated a broad spectrum of activity in models of epilepsy. In addition, ICA-105665 has also demonstrated activity in certain models of neuropathic pain.
Investigational
Matched Description: … of activity in models of epilepsy. ... ICA-105665 is a novel small molecule compound for the treatment of epilepsy. ... In addition, ICA-105665 has also demonstrated activity in certain models of neuropathic pain. …
An inhibitor of calcium-dependent isoforms of protein kinase C.[A253002,A253007]
Investigational
Matched Description: … An inhibitor of calcium-dependent isoforms of protein kinase C.[A253002,A253007] …
Maplirpacept is a recombinant fusion protein consisting of the CD47-binding domain of human signal regulatory protein alpha (SIRPa) linked to the IgG4 Fc region of human IgG.
Investigational
Matched Description: … Maplirpacept is a recombinant fusion protein consisting of the CD47-binding domain of human signal regulatory ... protein alpha (SIRPa) linked to the IgG4 Fc region of human IgG. …
NP-50301 is an ophthalmic therapeutic eye drop treating post-menopausal Dry Eye Syndrome (DES). It is being developed by Nascent Pharmaceuticals. It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S. The majority of sufferers of DES are...
Investigational
Matched Description: … It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over ... The majority of sufferers of DES are postmenopausal women; and clinical research around the world has ... suggested the benefits of both topical and systemic estrogen therapy in the treatment of DES in this …
SC12267 is a novel, small molecule agent from the class of DMARDs (disease modifying anti-rheumatic drug) for the therapy of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis. Through highly selective inhibition of pyrimidine biosynthesis, it controls the growth of rapidly proliferating cells, especially of lymphocytes, which are important...
Investigational
Matched Description: … Through highly selective inhibition of pyrimidine biosynthesis, it controls the growth of rapidly proliferating ... cells, especially of lymphocytes, which are important for the immune response. ... ) for the therapy of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis. …
Displaying drugs 10226 - 10250 of 12439 in total